1. Home
  2. CYTK vs CELH Comparison

CYTK vs CELH Comparison

Compare CYTK & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$78.68

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Logo Celsius Holdings Inc.

CELH

Celsius Holdings Inc.

HOLD

Current Price

$30.64

Market Cap

8.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
CELH
Founded
1997
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
8.5B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
CYTK
CELH
Price
$78.68
$30.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
17
Target Price
$89.26
$64.81
AVG Volume (30 Days)
1.7M
9.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.33
Revenue
$13,368,000.00
$1,318,014,000.00
Revenue This Year
$7.37
$37.04
Revenue Next Year
$310.19
$9.89
P/E Ratio
N/A
$91.21
Revenue Growth
N/A
101.65
52 Week Low
$31.99
$27.47
52 Week High
$80.20
$66.74

Technical Indicators

Market Signals
Indicator
CYTK
CELH
Relative Strength Index (RSI) 62.37 51.34
Support Level $59.07 $27.56
Resistance Level $79.66 $33.49
Average True Range (ATR) 3.20 1.60
MACD 0.51 0.31
Stochastic Oscillator 83.65 54.50

Price Performance

Historical Comparison
CYTK
CELH

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CELH Celsius Holdings Inc.

Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.

Share on Social Networks: